I am a translational R&D scientist and Scientific Director with over 15 years of experience developing therapies for rare neuromuscular and neurodegenerative disease. My expertise spans RNA-based therapeutics and gene therapy, from early discovery through clinical translation, with hands-on experience across academia and industry. My technical background includes antisense oligonucleotide (ASO) design and mechanism, exon-skipping […]
Thomas Brown, MD, MBA is Chief Medical Officer of Sygnomics, a startup applying systems biology & AI to help oncologists match cancer patients to personalized therapies. He is on the affiliate faculty at Institute for Systems Biology. He has more than two decades of oncology leadership spanning academic medicine, health-system administration, and health-tech innovation, including […]
Professor of Respiratory Immunology with expertise in translational immunology, inflammatory lung disease, pulmonary fibrosis and asthma. I advise on therapeutic target identification and validation, biomarker strategy, drug discovery and preclinical development. My research focuses on macrophage biology, immunometabolism and human experimental medicine. I have experience advising biotechnology and pharmaceutical companies on scientific strategy, therapeutic development […]
Physician-Founder and CEO of Predicate AI Labs, focused on developing next-generation health intelligence technologies at the intersection of AI, physiological computing, digital health, medical devices, and edge computing. My expertise includes health technology strategy, product development, clinical innovation, commercialization, strategic partnerships, global health, and early-stage venture development. I advise organizations on emerging technologies, market opportunities, […]
Hyoung Lee is a CMC (Chemistry, Manufacturing, and Controls) strategist and chemical development leader with over 20 years of experience in the pharmaceutical industry. He currently leads HIL CMC Consulting LLC, providing strategic guidance on chemical development and CMC-related activities for drug development programs.nnHis expertise spans chemical process development, manufacturing strategy, and quality considerations throughout […]
Mark Fyvie is a biopharma entrepreneur whose career began with a PhD from the University of Cambridge (UK). He has since built extensive experience across the biopharmaceutical industry, spanning research, drug development, and company building. He currently leads Vx Pharma, applying his scientific background and entrepreneurial acumen to assist clinical stage startups advance their therapeutic […]
Kevin Heath, MD, MPH, FACP is a board-certified internist and nephrologist who has spent his career inside one of the largest payer-provider enterprises in the country. He now leads Heath Clinical Intelligence Advisory, providing consulting expertise at the intersection of clinical medicine, population health, and integrated payer-provider strategy.nnHis expertise spans clinical operations, quality of care, […]
David Scieszka is the Founder and CEO of Vertical Longevity Pharmaceuticals, a biotechnology company focused on longevity science and therapeutics. In this role, he leads the company’s strategic vision, research direction, and business development efforts in the emerging longevity biotech space. He completed his PhD in biomedical sciences at The University of New Mexico School […]
I am a medical oncologist and drug developer dedicated to translating innovative science into breakthrough therapies for patients with cancer. As Executive Chair of Head & Neck Research at Sarah Cannon Research Institute, I am recognized as a key opinion leader in head & neck oncology, shaping the design and execution of early clinical development […]
With more than 35 years of experience, I have played a key role in the development and successful launch of innovative drug products, including Azilect® tablets and Copaxone® prefilled syringes. I have also contributed to the development of multiple drug candidates from discovery through late-stage clinical development. My experience spans innovative, generic, biosimilar, biologic, and […]